ARTICANZ - Beta (ver 0.91)
Annotated Registry of Trials in Cancer, Australia and New Zealand Ed.
- Results - target/MDM2-inhibitor
Home
By cancer type
By drug class
By site
Data
FAQ
About
⚠
ARTICANZ provides informational content about cancer drug trials in Australia/NZ that is updated weekly but may not be completely accurate, and should not replace medical advice from qualified healthcare professionals. The platform is intended to be useful, providing information "as is" without warranties. Non-medical users must always consult healthcare providers for all clinical decisions.
Search results
target/MDM2-inhibitor
3
trial(s) found.
NCT06479135
Haem
Phase 3
Recruiting
A Phase 3, Randomized, Double-blind, Add-on Study Evaluating the Safety and Efficacy of Navtemadlin Plus Ruxolitinib Vs Placebo Plus Ruxolitinib in JAK Inhibitor-Naïve Patients with Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib (
POIESIS
)
JAK1/JAK2 inhibitor
MDM2 inhibitor
placebo
Myelofibrosis
NSW
2217 - Kogarah - St George Hospital
2250 - Gosford - Central Coast Cancer Centre, Gosford Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3004 - Melbourne, Southbank - Alfred Health
3168 - Clayton - Monash Medical Centre
QLD
4814 - Douglas - Townsville Cancer Centre - The Townsville Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NCT03787602
Advanced
Phase 1 / Phase 2
Recruiting
A Phase 1b/2, Open-Label Study Evaluating the Safety and Efficacy of KRT-232 in Patients With p53 Wild-Type (p53WT) Merkel Cell Carcinoma (MCC) Who Have Failed Anti-PD-1 or Anti-PD-L1 Immunotherapy, or in Combination With Avelumab in MCC Patients Who Are Anti-PD-1 or Anti-PD-L1 Treatment Naïve (
KRT-232-103
)
MDM2 inhibitor
anti-PD-L1 monoclonal antibody
Merkel cell carcinoma
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
NCT03662126
Haem
Phase 2 / Phase 3
Recruiting
A Phase 2/3 Randomized, Controlled, Open-Label Study of KRT 232 in Subjects With Primary Myelofibrosis (PMF), Post Polycythemia Vera MF (Post-PV-MF), Or Post Essential Thrombocythemia MF (Post-ET-MF) Who Are Relapsed or Refractory to Janus Kinase (JAK) Inhibitor Treatment (
BOREAS
)
MDM2 inhibitor
Myelofibrosis
Polycythemia vera
VIC
3004 - Melbourne, Southbank - Alfred Health
3168 - Clayton - Monash Medical Centre
3174 - Noble Park - South Eastern Private Hospital
QLD
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
WA
6150 - Murdoch - Fiona Stanley Hospital
Additional search terms:
API and Webpage URLs:
Copy /Bookmark
Filters
Recruitment Status
Recruiting (3)
Recruitment Country and State
QLD (3)
SA (2)
VIC (2)
WA (2)
NSW (1)
Phase
Phase 1 / Phase 2 (1)
Phase 2 / Phase 3 (1)
Phase 3 (1)
Trial Type
Haem (2)
Advanced (1)
Cancer Therapy Class
MDM2
100%
JAK1
33%
JAK2
33%
PD-1/PD-L1
33%
PD-L1
33%
Facility
3004 - Melbourne, Southbank - Alfred Health (2)
3168 - Clayton - Monash Medical Centre (2)
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre (2)
2217 - Kogarah - St George Hospital (1)
2250 - Gosford - Central Coast Cancer Centre, Gosford Hospital (1)
2298 - Waratah - Calvary Mater Newcastle Medical Oncology (1)
3000 - Melbourne - Peter MacCallum Cancer Centre (1)
4814 - Douglas - Townsville Cancer Centre - The Townsville Hospital (1)
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre (1)
4102 - Woolloongabba - Princess Alexandra Hospital (1)
3174 - Noble Park - South Eastern Private Hospital (1)
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre (1)
6150 - Murdoch - Fiona Stanley Hospital (1)
Cancer Type
Cancer
Haematological malignancy
Myelofibrosis
Myeloproliferative neoplasm
Merkel cell carcinoma
Non-melanoma skin cancer
Skin cancer
Solid tumour
Polycythemia vera
URLs for this search
API URL:
Copy
Bookmarkable URL:
Copy